Gregg McConnell
Corporate Officer/Principal at TCR2 THERAPEUTICS INC.
Gregg McConnell active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TCR2 THERAPEUTICS INC. | Corporate Officer/Principal | 26/05/2020 | - |
Career history of Gregg McConnell
Former positions of Gregg McConnell
| Companies | Position | Start | End |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
BlueRock Therapeutics Canada ULC
 BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Corporate Officer/Principal | - | - |
Training of Gregg McConnell
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Cornell University | Undergraduate Degree |
| Zanvyl Krieger School of Arts & Sciences | Graduate Degree |
Statistics
International
| United States | 6 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private companies | 2 |
|---|---|
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
BlueRock Therapeutics Canada ULC
BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Health Technology |
- Stock Market
- Insiders
- Gregg McConnell
- Experience
